Let’s Be Clear!
Are you looking for the very best clear skin treatment for psoriasis, vitiligo, eczema or another light responsive disease? Or maybe, you’re seeking a safe alternative to biologic drugs that will work quickly, is affordable and will fit into your daily schedule? Not only will this section explain why you should choose phototherapy as your treatment, we will also explain why Daavlin Phototherapy is the clear choice for you! Thousands of hospitals, patients, dermatology clinics and universities around the world have chosen Daavlin. Our reputation for high-quality, technologically advanced phototherapy devices and outstanding customer service has made us a valuable partner in every one of these places.
There are Other Treatments,
So Why Choose Phototherapy?
Narrowband UVB phototherapy is considered a first-line treatment for many conditions such as psoriasis, vitiligo and eczema, is safe enough for pregnant women and children to use, and has none of the serious side effects associated with competing biological drug therapies.
For psoriasis, both Narrowband Phototherapy and PUVA have median clearance times of only 4-5 weeks. That means clear skin twice as fast as Enbrel, Stelara, Humira or Remicade!
In-office phototherapy treatments or the one-time cost of a home phototherapy unit are reasonably priced and may even be covered by some private insurance companies, depending on your country. Other treatments such as biological drug therapies can cost more than the price of an average car – EACH YEAR!
For decades, statistics have shown consistently high rates of clearance for both PUVA and Narrowband UVB. In addition, patients who stop using phototherapy seldom suffer from the flares or rebounds that are common with other treatments.
Compare the Safety of Phototherapy vs. Biological Drugs for the Treatment of Skin Disease
*Although appearing to be the most innocuous of the biologic drugs in the above comparison; Raptiva was removed from the U.S. market on April 8, 2009, due to the risk of PML, a fatal brain infection. Data compiled using MedWatch statistics available at FDA.gov Enbrel is a registered trademark of Amgen, Inc. / Wyeth Pharmaceuticals. Humira is a registered trademark of Abbott Laboratories. Remicade is a registered trademark of Centocor, Inc. Raptiva is a registered trademark of Genentech. Elidel is a registered trademark of Novartis. Protopic is a registered trademark of Astellas Pharma.
And, Why Choose Daavlin?
Daavlin Offers Better Customer Service
Daavlin has a network of international distributor’s offering and servicing Daavlin products in more than sixty countries around the world. Globally, dermatologists and home patients have been acquiring and trusting Daavlin devices to treat photoresponsive skin disorders such as psoriasis, vitiligo, and eczema (atopic dermatitis) for nearly 40 years.
Daavlin Dosimetry is More Accurate
Daavlin’s integrating Flex Dosimetry control systems are unmatched in the phototherapy marketplace and lead the industry in accuracy. No other system is as precise. This means increased safety and faster clearing, as well as more efficient use of ultraviolet lamps.
Daavlin Phototherapy Units are More Advanced
Only Daavlin can offer the latest new advances such as options like FlexRx and home dosimetry. No other phototherapy company is as dedicated to innovation and continuous improvement as Daavlin.
Home Dosimetry Facilitates Fast Clearing and Greater Patient Safety
Many patients are curious about the value of integrated dosimetry controllers on home phototherapy devices and specifically wonder what exact benefits are provided for the extra cost. Integrated dosimetry controllers like the Daavlin Flex dosimetry controller measure the actual light output of the phototherapy device in real time, and adjust the treatment length to give exactly the programmed dose. Some benefits can include:
- Faster clearing
- Less risk of burning
- A better chance of successful treatment
- Lower long term side effect risks
- More efficient use of expensive lamps
The easiest way to explain the advantage of integrated dosimetry is to show exactly what happens to the power output of a home phototherapy device as it warms up:
This chart describes the actual measured output of a phototherapy unit in the beginning moments of a treatment. Although not shown, at five minutes, the output in this test case was 22 milliwatts. Therefore, we can see that for the first minute, the lamps emit approximately half of the eventual calibrated output and that the power of the lamps is changing rapidly.
In this example, an initial 15-second treatment using a timer only controller would deliver a dose of 60mJ. If the patient then treated another part of his or her body for 15 seconds, that part of the body would receive about 120mJ in a 15 second treatment.
Or in another way of looking at it, if the desired dose had been 120 milliJoules, then the patient was underdosed by half. With a dosimetry controller, exactly the desired treatment is always given. Even small changes in room temperature, along with other factors, can significantly change the operating characteristics of the lamps.
Everyone is aware of the perils of overdosing, but under-dosing can significantly compromise treatment results as well. When receiving repeated, small, ineffective doses of UV radiation, the skin’s natural defense is photoadaptation. Therefore, the patient will require more treatments to achieve the desired outcome and will require larger doses than optimally necessary to overcome the blocking effects of the increasingly adapted skin. Moreover, not only will lower than prescribed dosages be less effective, they unnecessarily increase the total lifetime dose of UV radiation a patient requires for desired results with a consequent risk of greater long term side effects.
Integrating dosimetry is an effective and time tested way to deliver the exact dosages that have proven to be effective in the therapy of disease. And, integrating dosimeters’ greater therapeutic efficiency conserves lamp life by eliminating the need for stabilizing warm up times and the prolonged therapy caused by under-dosing.